The central role of B-cells in MS has been demonstrated through the effectiveness of anti-CD20 therapies, targeting B-lymphocytes exclusively.26 It is therefore thought-provoking that the other key component in immune mediated diseases, the CD4+ T-lymphocyte, is where HHV-7 resides.10 Here, CD4 is linked to myeloid sarcoma.